The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney.

Autor:	Wang Q; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.) qingping.wang@sanofi.com., Munteanu B; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Marker A; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Luo Y; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Holz C; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Kane JL Jr; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Kuntzweiler T; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Poulton EJ; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Sedic M; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Jayyosi Z; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Riedel J; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Fretland J; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.).
Jazyk:	angličtina
Zdroj:	Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Oct 16; Vol. 52 (11), pp. 1288-1296. Date of Electronic Publication: 2024 Oct 16.
DOI:	10.1124/dmd.124.001813
Abstrakt:	Solute carrier family 6 member 19 (SLC6A19) inhibitors are being studied as therapeutic agents for phenylketonuria. In this work, a potent SLC6A19 inhibitor (RA836) elevated rat kidney uremic toxin indoxyl sulfate (IDS) levels by intensity (arbitrary unit) of 13.7 ± 7.7 compared with vehicle 0.3 ± 0.1 ( P = 0.01) as determined by tissue mass spectrometry imaging analysis. We hypothesized that increased plasma and kidney levels of IDS could be caused by the simultaneous inhibition of both Slc6a19 and a kidney IDS transporter responsible for excretion of IDS into urine. To test this, we first confirmed the formation of IDS through tryptophan metabolism by feeding rats a Trp-free diet. Inhibiting Slc6a19 with RA836 led to increased IDS in these rats. Next, RA836 and its key metabolites were evaluated in vitro for inhibiting kidney transporters such as organic anion transporter (OAT)1, OAT3, and breast cancer resistance protein (BCRP). RA836 inhibits BCRP with an IC 50 of 0.045 μ M but shows no significant inhibition of OAT1 or OAT3. Finally, RA836 analogs with either potent or no inhibition of SLC6A19 and/or BCRP were synthesized and administered to rats fed a normal diet. Plasma and kidney samples were collected to quantify IDS using liquid chromatography-mass spectrometry. Neither a SLC6A19 inactive but potent BCRP inhibitor nor a SLC6A19 active but weak BCRP inhibitor raised IDS levels, whereas compounds inhibiting both transporters caused IDS accumulation in rat plasma and kidney, supporting the hypothesis that rat Bcrp contributes to the excretion of IDS. In summary, we identified that inhibiting Slc6a19 increases IDS formation, while simultaneously inhibiting Bcrp results in IDS accumulation in the kidney and plasma. SIGNIFICANCE STATEMENT: This is the first publication to decipher the mechanism for accumulation of indoxyl sulfate (IDS) (a uremic toxin) in rats via inhibition of both Slc6a19 and Bcrp. Specifically, inhibition of Slc6a19 in the gastrointestinal track increases IDS formation, and inhibition of Bcrp in the kidney blocks IDS excretion. Therefore, we should avoid inhibiting both solute carrier family 6 member 19 and breast cancer resistance protein simultaneously in humans to prevent accumulation of IDS, a known risk factor for cardiovascular disease, psychic anxiety, and mortality in chronic kidney disease patients. (Copyright © 2024 by The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu